Project Grant R01CA289260
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$683K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $997,410 to Arizona State University to develop noninvasive MRI-based methods for detecting and differentiating between two high-grade glioma subtypes - the neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes. The researchers will leverage quantitative diffusion MRI to map the microstructural signatures of the NEU subtype's neurite-like microtubes, as...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979.00 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding and disrupting tumor metabolism and enhancing anti-tumor immunity in diffuse midline gliomas (DMGs), a type of aggressive pediatric brain cancer. The key goals are to: 1) Delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1...
This Project Grant award of $699,125 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the potential of targeting the enzyme 2-oxoglutarate dehydrogenase (OGDH) as a novel therapy for glioblastoma, the most common and deadly form of brain cancer. The research will build on the grantee's prior findings that OGDH is a critical driver of...
This Project Grant award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research aimed at developing combination metabolic therapy and imaging techniques for treating diffuse midline gliomas (DMGs), a devastating form of brain cancer in children. The $670,904 grant awarded to the University of California, San Francisco (UCSF) will fund research to determine if combined inhibition of the metabolic enzymes G6PD and GLO1 can abrogate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $954,000 to the University of Pittsburgh to conduct research aimed at understanding how aging promotes the growth of glioblastoma, an aggressive form of brain cancer. The project will leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to investigate how aging reprograms the tumor immune microenvironment and cell autonomous nuclear...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,974 in funding to The Ohio State University to investigate the therapeutic potential of targeting the KIF20A protein in glioblastoma, an aggressive brain cancer. The research aims to characterize the role of KIF20A in early mitosis and evaluate the impact of a KIF20A inhibitor as a single agent and in combination with radiation therapy in glioblastoma patient-derived models. The...
This award provides funding for research into the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, a lethal complication of cancer. The award is a $730,398 Project Grant funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396). The research is being conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization in...
The National Cancer Institute (NCI) awarded a $800,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Creative Biotherapeutics LLC, a for-profit biotechnology firm, to develop a novel biologic therapy for eradicating brain cancer and brain metastases. The research aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant brain tumors, in order to induce apoptosis, overcome drug/immune resistance, and reduce the need for highly...
This federal Project Grant award of $898,209 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research conducted by the Dana-Farber Cancer Institute (DFCI) to better understand the molecular mechanisms underlying glioma formation and DNA damage response in brain tumors with mutations in the IDH1 gene. The research objectives include determining the response of a genetically engineered mouse model of IDH1-mutant grade 3 astrocytoma to IDH1 inhibitors and...